The classic website will no longer be available as of June 25, 2024. Please use the modernized

Key Record Dates Identifier: NCT06041802
Brief Title: A Study of MK-3475A (Pembrolizumab Formulated With MK-5180) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)

First Submitted : September 11, 2023
First Submitted that Met QC Criteria : September 11, 2023
First Posted : September 18, 2023

Last Update Submitted that Met QC Criteria : April 19, 2024
Last Update Posted : April 22, 2024